Alnylam Buoyed By Early Alzheimer’s Gene Silencing Success
Targets Early Disease-Causing Protein
Alnylam has unveiled Phase I data showing its RNAi candidate can eliminate the amyloid precursor protein in the brain – opening the door to treating Alzheimer’s and many more CNS diseases.
